PT  - JOURNAL ARTICLE
AU  - Romero-Pinedo, Salvador
AU  - Quesada, Marina
AU  - Álvarez-Fernández, Stela
AU  - Olmo, Asunción
AU  - Abia, David
AU  - Alarcón, Balbino
AU  - Delgado, Pilar
TI  - Longitudinal and comparative analysis of humoral response upon COVID-19 vaccination
AID  - 10.1101/2021.10.14.21264762
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.14.21264762
4099  - http://medrxiv.org/content/early/2021/10/20/2021.10.14.21264762.short
4100  - http://medrxiv.org/content/early/2021/10/20/2021.10.14.21264762.full
AB  - The emergence of COVID-19 has led to a worldwide challenge for the rapid development of vaccines. Several types of safe and effective vaccines have been available in a time frame never seen before. Comparative studies to know the extent of protection and the immune response elicited by the different vaccines are of outstanding utility. Here, as a correlate for protection, we perform a comparative study of the humoral response to three vaccines, ChAdOx1 (Oxford-AstraZeneca), mRNA-1273 (Moderna), and BNT162b2 (Pfizer-BioNTech) by applying a flow cytometry-based highly sensitive method that we had previously developed. We have found that mRNA vaccines (mRNA-1273 and BNT162b2) induce a stronger humoral response that lasts for at least 6 months after vaccination. We also show that only one dose of BNT162b2 is enough to achieve the maximum response in seropositive pre-vaccination donors.Competing Interest StatementThe authors have issued a patent application owned by CSIC.Funding StatementThis work was funded by intramural grant CSIC-COVID19-004: 202020E081Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Autonomous University of Madrid Research Ethics Committee gave ethical approval for this work (no. # 2352)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript